RxDoctor Payments Data

Deena Jacob, MD

Family Medicine · Sayre, PANPI 1598105843

Payments from drug & device makers

$486in general payments, 2019–2025

Across 11 payments — averaging $44.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$127
  • Pfizer$113
  • GSK$96
  • Sanofi-aventis U.S. LLC$95
  • Amgen$15
  • Gilead$15
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie2$127
Pfizer2$113
GSK2$96
Sanofi-aventis U.S. LLC1$95
Amgen1$15
Gilead1$15
Abbott1$13
Lilly USA, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$486 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$100,269
Medicare patients
323
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$98,099
JardianceEmpagliflozin61$68,838
OzempicSemaglutide56$52,228
JanuviaSitagliptin Phosphate25$27,351
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,654
Combivent RespimatIpratropium/Albuterol Sulfate12$16,559
XareltoRivaroxaban19$15,279
TrulicityDulaglutide15$13,828
JanumetSitagliptin Phos/Metformin Hcl15$10,687
Breo ElliptaFluticasone/Vilanterol21$8,921
Atorvastatin Calcium559$5,836
DuleraMometasone/Formoterol14$4,858
BrilintaTicagrelor11$4,831
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,733
Adderall XrDextroamphetamine/Amphetamine22$4,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$98,09985 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$96$28,18951 claims
Lilly USA, LLCTrulicity$12$13,82815 claims
AbbVieSynthroid$127$3,53967 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Sayre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →